tbuckley/cabot-search huggingface dataset:
Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?
Authors: Sawa Ito, Minoo Battiwalla, J. Joseph Melenhorst, Mattias Carlsten, Angelique Biancotto, Ena Wang, Zhi Xie, Pawel Muranski, Matthew J. Olnes, Kazushi Tanimoto, Paula Schum, Shira Perl, Howard Dickler, J. Philip McCoy, Thomas Hughes, Leodayan Bojanowski, Nancy F. Hensel, Neal S. Young, A. John Barrett
Journal: Blood (2012)
Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL).
Authors: Gregory A. Hale, Smriti Shrestha, Jennifer LeRademacher, Hillard M Lazarus, Ginna G. Laport, Silvia Montoto, Parameswaran N Hari
Journal: Blood (2009)
Genetic Polymorphisms Associated with Risk for Pulmonary Hypertension and Proteinuria in Sickle Cell Disease.
Authors: Allison E. Ashley-Koch, Laura De Castro, Felicia Lennon-Graham, Jude Jonassaint, Terry L. Jackson, Jennifer Price, Jason Galloway, Ken I. Ataga, Eugene P. Orringer, Jeffery M. Vance, Marilyn J. Telen
Journal: Blood (2004)
Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Authors: Roy Fleischmann, Janet van Adelsberg, Yong Lin, Geraldo da Rocha Castelar‐Pinheiro, Jan Brzezicki, Pawel Hrycaj, Neil M. H. Graham, Hubert van Hoogstraten, Deborah Bauer, Gerd R. Burmester
Journal: Arthritis & Rheumatology (2016)

To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy.Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co-primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed.The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, -0.46 [P = 0.0007]; for 200 mg, -0.47 [P = 0.0004]) versus placebo (-0.26). Infections were the most frequently reported treatment-emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections.Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti-TNF agents. Safety data were consistent with interleukin-6 receptor blockade and the known safety profile of sarilumab.
2016 update of the EULAR recommendations for the management of early arthritis
Authors: Bernard Combe, Robert Landewe, Claire I Daien, Charlotte Hua, Daniel Aletaha, Jose María Álvaro-Gracia, Margôt Bakkers, Nina Brodin, Gerd R Burmester, Catalin Codreanu, Richard Conway, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Joao Fonseca, Karim Raza, Lucía Silva-Fernández, Josef S Smolen, Diana Skingle, Zoltan Szekanecz, Tore K Kvien, Annette van der Helm-van Mil, Ronald van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis. <h3>Methods</h3> In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of 'management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process. <h3>Results</h3> The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research. <h3>Conclusions</h3> These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
OC-017 International Multicentre Study Assessing the Effects of Anti-Thrombotic Use in Patients with Upper GI Bleeding
Authors: P Dunne, SB Laursen, L Laine, H Dalton, JH Ngu, M Schultz, I Murray, A Rahman, A Anderloni, A Stanley
Journal: Gut (2016)

<h3>Introduction</h3> Anti-thrombotics (antiplatelets and anticoagulants; ATs) have been identified as risk factors for upper gastrointestinal bleeding (UGIB). However few international studies have evaluated their effect on patient outcome. We aimed to assess the effects of AT use on outcome in patients with high-risk UGIB requiring endoscopic therapy. <h3>Methods</h3> Patients presenting with UGIB who required endoscopic therapy at eight centres (Scotland, England, USA, Canada, Denmark, Italy, Singapore &amp; New Zealand) were prospectively included over 12 months. Data recorded included the full Rockall score (FRS); AT use (Aspirin, Adenosine Diphosphate Receptor Inhibitors (ADP-RI), Vitamin-K Antagonists (VKA), Low Molecular Weight Heparin (LMWH), Thrombin inhibitors and Factor Xa inhibitors); endoscopic findings; blood transfusion; interventional radiology; surgery; rebleeding; 30 day mortality and length of hospital stay. <h3>Results</h3> Out of 3154 patients, 619 required endotherapy (44% for ulcer bleeding and 21% for varices). 187 (30%) patients were on aspirin, 61 (11%) ADP-RI, 57 (9%) VKA, 8 (1%) LMWH, 7 (1%) factor Xa-inhibitor and 1 patient a thrombin-inhibitor. 63 (11%) patients were treated with &gt;1 type of AT. Patients treated with ATs were older (p &lt; 0.0001), had higher ASA-score (p = 0.001), lower haemoglobin (P = 0.04), higher FRS (p &lt; 0.0001), more frequently had ischaemic heart disease (IHD; p &lt; 0.001), less frequently had cirrhosis (P &lt; 0.001), more frequently bled from ulcers (p &lt; 0.001) but less frequently from varices (p &lt; 0.001) compared with those not taking ATs. There were no differences in sex, systolic blood pressure, frequency of malignancies, need for surgery/embolisation or rebleeding rate. Patients taking ATs had lower mortality than those not taking these drugs: all cause (11/253 [4%] vs 37/315 [12%]; p = 0.006) and bleeding-related (3/253 [1%] vs 19/315 [6%]; p = 0.01). However, when excluding patients with liver cirrhosis (n = 151) there were no differences in mortality between groups. <h3>Conclusion</h3> Patients with UGIB who require endoscopic therapy whilst on ATs do not experience a higher rate of rebleeding or mortality compared with UGIB patients who do not use ATs. We observed excess mortality in patients not taking ATs, which is likely due to the high rates of cirrhosis (40%) and variceal bleeding (33%) in these patients. Further studies are needed to clarify the risk of adverse outcome following UGIB in patients taking novel ATs. <h3>Disclosure of Interest</h3> None Declared
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.
Authors: Paul Richardson, Sundar Jagannath, Noopur Raje, Andrzej Jakubowiak, Sagar Lonial, David Avigan, Irene Ghobrial, Robert Schlossman, Amitabha Mazumder, Nikhil Munshi, Robin Joyce, Deborah Doss, Diane Warren, Stephen Hayes, Lawrence Giove, S. Kaster, Carol Delaney, Marisa Lauria, Constantine Mitsiades, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Kenneth Anderson
Journal: Blood (2007)
Autoimmune Cytopenia in Chronic Lymphocytic Leukemia: Effect on Outcome and Survival, a Population Based Analysis in British Columbia, Canada
Authors: Alaa A Alzaki, Alina S Gerrie, Tanya L. Gillan, Steven Huang, Miriam Ahmed, Cynthia L. Toze, Heather A Leitch, Khaled M Ramadan
Journal: Blood (2014)
Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature
Authors: Zohar Sachs, Hanh Nguyen, Nurul Azyan Mohd Hassan, Susan K Rathe, Karen Sachs, Ernesto Diaz-Flores, Sean C Bendall, Miechaleen D Diers, Garry P. Nolan, Kevin M. Shannon, David A. Largaespada
Journal: Blood (2012)
Prasugrel (CS-747, LY640315) Hydrochloride, a Novel Thienopyridine Prodrug, Shows Potent Antiplatelet and Antithrombotic Effects with Rapid Onset of Action in Rats.
Authors: Yoichi Niitsu, Taketoshi Ogawa, Atsuhiro Sugidachi, Joseph A. Jakubowski, Yuki Yokouchi, Mayumi Kakusaka, Michihiro Hasegawa, Fumitoshi Asai
Journal: Blood (2005)
Elevated Red Cell Reduced Glutathione Is a Novel Biomarker of Diamond-Blackfan Anemia
Authors: Taiju Utsugisawa, Toshitaka Uchiyama, Hiromi Ogura, Takako Aoki, Isao Hamaguchi, Akira Ishiguro, Akira Ohara, Seiji Kojima, Shouichi Ohga, Etsuro Ito, Hitoshi Kanno
Journal: Blood (2014)
SP0044 Functional Consequences of Hand Osteoarthritis
Authors: K. Dziedzic
Journal: Annals of the Rheumatic Diseases (2016)

Hand osteoarthritis (OA) is not a single disease but a group of complex conditions ranging from a syndrome of joint pain accompanied by functional limitation to highly characterised subsets of radiographic hand OA. Whilst hand OA is one of the commonest forms of osteoarthritis there is a "knowledge-to-practice" gap in recognising and addressing functional consequences of hand OA across the clinical pathway. This presentation will consider functional consequences of hand OA at four levels: societal (population level); health care delivery (organisational level); health care professional level; and the impact on the person living with hand OA (individual level). It will draw on findings from three large cohorts of adults 50 years and over studied in North West Midlands, UK (n=30,000) (1–3) to describe the functional consequences of hand OA at a population level. Findings from a randomised controlled trial (3), an implementation study (4) and qualitative data (5) will be used to illustrate health care (e.g. primary care; occupational therapy) for the functional consequences of hand OA. The impact on the individual will be described using qualitative data of participant experiences of living with hand OA (6). Proposals for closing the "knowledge-to-practice" gap for the functional consequences of hand OA will be discussed. <h3>References</h3> Dziedzic K, Thomas E, Hill S, et al. The impact of musculoskeletal hand problems in older adults: findings from the North Staffordshire Osteoarthritis Project (NorStOP). Rheumatology (Oxford). 2007Jun;46(6):963–7. Myers H, Nicholls E, Handy J, et al. The Clinical Assessment Study of the Hand (CAS-HA): a prospective study of musculoskeletal hand problems in the general population. BMC Musculoskelet Disord. 2007 Aug 30;8:85. Dziedzic K, Nicholls E, Hill S, et al. Self-management approaches for osteoarthritis in the hand: a 2×2 factorial randomised trial. Ann Rheum Dis. 2015 Jan;74(1):108–18. Dziedzic KS, Healey EL, Porcheret M, et al. Implementing the NICE osteoarthritis guidelines: a mixed methods study and cluster randomised trial of a model osteoarthritis consultation in primary care – the Management of OsteoArthritis In Consultations (MOSAICS) study protocol. Implement Sci. 2014 Aug 27;9:95. Hill S, Dziedzic KS, Nio Ong B. Patients9 perceptions of the treatment and management of hand osteoarthritis: a focus group enquiry. Disabil Rehabil. 2011;33(19–20):1866–72. Hill S, Dziedzic KS, Ong BN. The functional and psychological impact of hand osteoarthritis. Chronic Illn. 2010 Jun;6(2):101–10. <h3>Disclosure of Interest</h3> None declared
Implication of STAT-5 Recruitment in the Expression of IRF-8 and in the Impairment of Human Plasmacytoid Dendritic Cells Differentiation Induced by BCR-ABL and GM-CSF
Authors: Anne Barra, Lucie Brault, Ali G Turhan, Lydia Roy, François Guilhot, Jean-Marc Gombert
Journal: Blood (2008)
THU0532 Genetic Analysis for P2x7R rs3751142 and CARD8 rs2043211 Polymorphisms for Susceptibility of Gout in Male Korean Population
Authors: S.-K. Kim, S.W. Lee, S.-S. Lee, D.H. Oh, D.-J. Park, H.-S. Kim, J.R. Choi, W.T. Chung, J.-Y. Choe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The NLRP3 inflammasome, a member of the NLR family, is a key player in the production of uric acid-mediated IL-1β and is an important cytoplasmic protein complex involved in gouty inflammation. Recent single-nucleotide polymorphism (SNP) studies suggested that genetic alternations of several target molecules such as CARD8 and P2X7R contribute to the process of NLRP3 inflammasome activation. <h3>Objectives</h3> The aim of this study was to determine the association between P2X7R rs3751142 and CARD8 rs2043211 polymorphisms and gout susceptibility in male Korean subjects. <h3>Methods</h3> This study enrolled a total 242 male patients with gout and 280 healthy controls. The polymorphisms of two individual genes including rs3751142 (C&gt;A) in the P2X7R gene and rs2043211 (A&gt;T) in the CARD8 gene were assessed using Taq-Man analysis. Statistical analyses were performed using the Chi-square test, Kruskal-Wallis test, and logistic regression analyses. <h3>Results</h3> A difference in genotypic frequency of the P2X7R rs3751142 and CARD8 rs2043211 genes was not detected between gout and control patients. Clinical parameters including age, onset age, disease duration, body mass index, and serum uric acid levels were not different among the three genotypes for either P2X7R or CARD8 (<i>p</i>&gt;0.05 for all). A pair-wise comparison of P2X7R rs3751142 and CARD8 rs2043211 genotype combinations revealed a protective effect of P2X7R/CARD8 AA/AA against gout susceptibility (OR=0.023, 95% CI 0.874–0.999). <h3>Conclusions</h3> This study revealed that genetic variability of the P2X7R rs3751142 and CARD8 rs2043211 genes might, in part, be associated with susceptibility for gout. <h3>References</h3> Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–41. Choe JY, Jung HY, Park KY, et al. Enhanced p62 expression through impaired proteasomal degradation is involved in caspase-1 activation in monosodium urate crystal-induced interleukin-1b expression. Rheumatology (Oxford) 2014;53:1043–53. Yang SK, Kim H, Hong M, et al. Association of CARD8 with inflammatory bowel disease in Koreans. J Hum Genet 2011;56:217–23. Chen Y, Ren X, Li C, et al. CARD8 rs2043211 polymorphism is associated with gout in a Chinese male population. Cell Physiol Biochem 2015;35:1394–400. Gu BJ, Zhang W, Worthington RA, et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001;276:11135–42. <h3>Disclosure of Interest</h3> None declared
Saturated fat and heart disease
Authors: Russell J de Souza, Sonia S Anand
Journal: BMJ (2016)

A new focus on whole dietary patterns should clear some of the confusion

Recent meta-analyses,1 2 3 commentaries,4 5 and bestselling books6 7 have called for an end to the proscription of saturated fats (SFAs), reversing years of dietary advice. Advocates of this shift draw support from prospective cohort studies since 1984, which when pooled find no association between SFA and risk of cardiovascular diseases.1 2 3 Limitations of this work include measurement error in assessment of diet, the choice of carbohydrate as the comparison nutrient, inconsistent adjustment for other dietary and lifestyle factors, and over-adjustment for changes in risk factors on the causal pathway. All will modify relations between SFAs and cardiovascular disease outcomes.

In this issue, Zong and colleagues (doi:10.1136/bmj.i5796) report the results of a pooled prospective cohort study of the association of dietary SFAs and coronary heart disease in male health professionals (Health Professionals Follow-up Study) and female nurses (Nurses’ Health Study).8 They report that around a 5% higher intake of longer chain dietary SFAs (12-18 carbons), found in hard cheese, whole milk, butter, beef, and chocolate, is associated with a 25% increased risk of coronary heart disease during 24-28 …
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (&gt;75 years) PATIENTS
Authors: Simona Sica, Massimo Breccia, Francesco Autore, Roberto Latagliata, Elisabetta Abruzzese, Giovanna Rege Cambrin, Antonella Gozzini, Francesca Celesti, Dario Ferrero, Fabio Stagno, Luigia Luciano, Fausto Castagnetti, Mario Annunziata, Francesco Cavazzini, Pellegrino Musto, Patrizia Pregno, Antonella Russo Rossi, Mario Tiribelli, Giuseppe Visani, Gianantonio Rosti, Giuliana Alimena
Journal: Blood (2011)
Experimental, Systems, and Computational Approaches to Understanding the MicroRNA-Mediated Reparative Potential of Cardiac Progenitor Cell–Derived Exosomes From Pediatric Patients
Authors: Udit Agarwal, Alex George, Srishti Bhutani, Shohini Ghosh-Choudhary, Joshua T. Maxwell, Milton E. Brown, Yash Mehta, Manu O. Platt, Yaxuan Liang, Susmita Sahoo, Michael E. Davis
Journal: Circulation Research (2016)

Rationale : Studies have demonstrated that exosomes can repair cardiac tissue post–myocardial infarction and recapitulate the benefits of cellular therapy. Objective : We evaluated the role of donor age and hypoxia of human pediatric cardiac progenitor cell (CPC)–derived exosomes in a rat model of ischemia–reperfusion injury. Methods and Results : Human CPCs from the right atrial appendages from children of different ages undergoing cardiac surgery for congenital heart defects were isolated and cultured under hypoxic or normoxic conditions. Exosomes were isolated from the culture-conditioned media and delivered to athymic rats after ischemia–reperfusion injury. Echocardiography at day 3 post–myocardial infarction suggested statistically improved function in neonatal hypoxic and neonatal normoxic groups compared with saline-treated controls. At 28 days post–myocardial infarction, exosomes derived from neonatal normoxia, neonatal hypoxia, infant hypoxia, and child hypoxia significantly improved cardiac function compared with those from saline-treated controls. Staining showed decreased fibrosis and improved angiogenesis in hypoxic groups compared with controls. Finally, using sequencing data, a computational model was generated to link microRNA levels to specific outcomes. Conclusions : CPC exosomes derived from neonates improved cardiac function independent of culture oxygen levels, whereas CPC exosomes from older children were not reparative unless subjected to hypoxic conditions. Cardiac functional improvements were associated with increased angiogenesis, reduced fibrosis, and improved hypertrophy, resulting in improved cardiac function; however, mechanisms for normoxic neonatal CPC exosomes improved function independent of those mechanisms. This is the first study of its kind demonstrating that donor age and oxygen content in the microenvironment significantly alter the efficacy of human CPC-derived exosomes.
FRI0636-HPR Effects of Clinical Pilates Exercises Combined with Dancetherapy on Mood in Patients with Rheumatic Diseases: Table 1.
Authors: P. Kisacik, G. Arin, S. Oksuz, U. Berberoglu, G. Arın, A. Akdogan, A. Akdogan, O. Dogan, O. Dogan, E. Karabulut, E. Karabulut, E. Unal, E. Unal
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Clinical pilates exercises are described as mind-body exercise models which are also recommended on treatment of rheumatic diseases (1, 2). Since dancetherapy has positive effects on mood, it has been preferred in the rehabilitation of the chronic diseases in recent years (3,4). However, clinical pilates exercises combined with dancetherapy in rheumatic patients is not found in the literature. <h3>Objectives</h3> To investigate the effects of clinical pilates exercise combined with dancetherapy on mood in rheumatic patients. <h3>Methods</h3> 20 rheumatic patients aged 42.00±12.00 years were participated in this study. Mood status of the patients were assessed by Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS) and The Multidimensional Scale of Perceived Social Support (MSPSS). Patients performed supervised clinical pilates exercises in a period of one hour, 3 times a week for 10 weeks. Dancetherapy was added to only 12 of patients9 program once a week, one hour, for 10 weeks. <h3>Results</h3> All scores improved in all patients9 for the post-exercise assessments relevant to the pre-exercise assessments. However, statistically significant improvement were observed only in MSPSS scores for the patients participated to the dancetherapy sessions (p&lt;0.05) (Table.1). <h3>Conclusions</h3> Clinical pilates exercises may provide improvement in mood characteristics in rheumatic patients. We concluded that these exercises enhance patients social support perceptions when combined with dancetherapy. <h3>References</h3> Yakut E, Yağlı NV, Akdogan A, Kiraz S. The role of Pilates exercises in patients with osteoarthritis of knee: a pilot study. J Turkish Physiotherapy and Rehabilitation 2006;17(2):51–60. Dinas PC, Koutedakis Y, Flouris AD. Effects of exercise and physical activity on depression. Irish journal of medical science. 2011;180(2):319–25. Belardinelli R, Lacalaprice F, Ventrella C, Volpe L, Faccenda E. Waltz dancing in patients with chronic heart failure: new form of exercise training. Circulation Heart failure. 2008;1(2):107–14. Hackney ME, Earhart GM. Effects of dance on movement control in Parkinson9s disease: a comparison of Argentine tango and American ballroom. Journal of rehabilitation medicine. 2009;41(6):475–81. <h3>Disclosure of Interest</h3> None declared
A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma
Authors: Bertrand Coiffier, Evgenii Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz C Offner, Simon A. Rule, Adriana Teixeira, Jan A Walewski, Michael Crump, Ofer Shpilberg, Robert Hermann, Sudha Parasuraman, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani
Journal: Blood (2010)